trial · primary record
Azercabtagene zapreleucel (azer-cel)
B-cell Mediated Autoimmune Disorders
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2029-01-01 |
| Primary endpoint | Number of Participants with Dose-Limiting Toxicities (DLTs) |
| Registry ID | NCT06680037 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:13.592Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06680037
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.